DelveInsight’s “Immune Thrombocytopenia Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Immune Thrombocytopenia, historical and forecasted epidemiology as well as the Immune Thrombocytopenia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock detailed insights into the Immune Thrombocytopenia Market by downloading the comprehensive report from DelveInsight @ Immune Thrombocytopenia Therapeutics Market

Key Takeaways from the Immune Thrombocytopenia Market Report

• In December 2025, Incyte Corporation initiated a Phase 2a study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
• In December 2025, Eli Lilly and Company conducted a study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.
• In December 2025, Novartis Pharmaceuticals announced a study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
• In December 2025, argenx initiated a study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1).
• In the 7MM, the US accounted for the highest number of Immune Thrombocytopenia Prevalence Cases with nearly 66,500 in 2023. These cases are expected to increase during the forecast period.
• Among the age-specific cases, the Immune Thrombocytopenia Prevalence among adults is much more than that among children.
• Among the gender-specific cases, there were nearly 20,600 Immune Thrombocytopenia diagnosed prevalence cases among males and nearly 35,000 cases among females in the US in 2023.
• Among EU4 and the UK, the UK accounted for the highest number of Immune Thrombocytopenia prevalence cases, followed by Germany. Whereas Spain occupied the bottom of the ladder.
• The leading Immune Thrombocytopenia Companies such as Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.
• Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.

Gain a competitive edge in the Immune Thrombocytopenia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Immune Thrombocytopenia Treatment Drugs

Immune Thrombocytopenia Epidemiology Segmentation in the 7MM

• Total Immune Thrombocytopenia Prevalent Cases
• Immune Thrombocytopenia Age-specific Diagnosed Prevalent Cases
• Immune Thrombocytopenia Gender-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Immune Thrombocytopenia Epidemiology Trends @ Immune Thrombocytopenia Prevalence

Marketed Immune Thrombocytopenia Drugs

• TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical

Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally bioavailable investigational agent developed by Rigel Pharmaceuticals and approved for treating patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. It inhibits FcR-triggered, SYK-dependent cytoskeletal rearrangement during phagocytosis. As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. It was approved by the US FDA in April 2018.

• DOPTELET (avatrombopag): Sobi (Dova Pharmaceuticals)

DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic Immune Thrombocytopenia who have had an insufficient response to previous treatment. In June 2019, the US FDA approved Dova Pharmaceuticals’ supplemental New Drug Application (sNDA) for expanding DOPTELET use. The drug is indicated for the treatment of thrombocytopenia in adults with chronic Immune Thrombocytopenia who have had an insufficient response to a previous treatment.

Emerging Immune Thrombocytopenia Drugs

• Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma

Rilzabrutinib is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase, a key player in signaling pathways downstream of the B-cell receptor (BCR) and Fc receptors. By blocking BTK activation, it regulates B-cell maturation and immune cell activation without depleting B-cells. This fast-acting therapy holds promise for treating autoimmune and inflammatory diseases. Rilzabrutinib is currently in the Phase III stage of development to treat Immune Thrombocytopenia in adults and adolescents with persistent or chronic Immune Thrombocytopenia. The company is anticipating the submission in 2024.

• Mezagitamab: Millennium Pharmaceuticals/Takeda

Mezagitamab is a subcutaneously administered human monoclonal antibody (human IgG1 lambda) that binds to the CD38 transmembrane glycoprotein expressed on the surface of cells and can deplete those cells by distinct mechanisms.

Discover key developments and opportunities in the Immune Thrombocytopenia Market. Click here to learn more from DelveInsight’s latest report @ Immune Thrombocytopenia Market Size

Immune Thrombocytopenia Companies

Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.

Immune Thrombocytopenia Market Outlook

The need to avoid the less effective immune suppressants has led to the development of new more targeted treatments for Immune Thrombocytopenia, starting with the second-generation TPO-RAs and now including SYK inhibition with other classes of treatment in clinical development. The introduction of these novel therapies has allowed to use of less immune suppression in Immune Thrombocytopenia management. Over the last decade, there has been a shift away from immune suppression for the treatment of Immune Thrombocytopenia.

Download DelveInsight’s Immune Thrombocytopenia Market report today and stay ahead in this rapidly evolving field. @ Immune Thrombocytopenia Clinical Trials

Scope of the Immune Thrombocytopenia Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Immune Thrombocytopenia Companies- Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company, and others.
• Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
• Immune Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Immune Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Immune Thrombocytopenia Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Immune Thrombocytopenia Market Report Introduction

3. Country-wise Immune Thrombocytopenia Market Overview at a Glance

4. Immune Thrombocytopenia Market Overview by Therapeutic Class

5. Methodology of Immune Thrombocytopenia Epidemiology and Market

6. Immune Thrombocytopenia Executive Summary

7. Key Events

8. Immune Thrombocytopenia Disease Background and Overview

9. Immune Thrombocytopenia Epidemiology and Patient Population

10. Immune Thrombocytopenia Patient Journey

11. Immune Thrombocytopenia Marketed Drugs

12. Immune Thrombocytopenia Emerging Drugs

13. Immune Thrombocytopenia: Market Analysis

14. Key Opinion Leaders’ Views

15. Immune Thrombocytopenia SWOT Analysis

16. Immune Thrombocytopenia Unmet needs

17. Immune Thrombocytopenia Market Access and Reimbursement

18. Appendix

19. Immune Thrombocytopenia Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market